antibiotics 2015 in icu
TRANSCRIPT
![Page 1: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/1.jpg)
ANTIBIOTICS2015 IN ICUSAMIR EL ANSARY
![Page 2: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/2.jpg)
https://www.facebook.com/groups/1451610115129555/#!/groups/1451610115129555/
Wellcome in our new group ..... Dr.SAMIR EL ANSARY
![Page 3: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/3.jpg)
Critical Care Antibiotics
![Page 4: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/4.jpg)
Definitions
• Minimum Inhibitory Concentration
– Antimicrobial concentration that inhibits visible microbial growth in artificial media
• Gram Stain
– Gram positive
– Gram negative
• Acid fast
![Page 5: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/5.jpg)
• Problems with MIC:
•Fixed drug concentration•All or none parameter. Growth vs. no growth•Does not provide information on the time course of
antimicrobial activity•Drug concentrations change throughout the dosing
interval•Does not capture interpatient pharmacokinetic
variability•Does not provide info on post-antibiotic effects
![Page 6: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/6.jpg)
Gram staining
FOR differentiating bacterialspecies into (gram-positive and gram-negative).
The name comes from its inventor, Hans Christian Gram.
Gram staining differentiates bacteria by the chemical and physical properties of their cell walls by detecting peptidoglycan, which is present in a thick layer in gram-positive bacteria.
![Page 7: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/7.jpg)
Gram staining
In a Gram stain test, gram-positive bacteria retain the crystal violet dye, while a counterstain
(commonly safranin or fuchsine) added after the crystal violet gives all gram-negative
bacteria a red or pink coloring.
![Page 8: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/8.jpg)
Acid-fastness
A physical property of certain bacteria (and, less commonly, protozoa), specifically their resistance to decolorization by acids during staining procedures.
The high mycolic acid content of certain Protozoa cell walls, and those of Mycobacteria, is responsible for the staining pattern of poor absorption followed by high retention. Usually used to identify mycobacteria.
![Page 9: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/9.jpg)
Pharmacodynamics
Time Dependent Killing
• Beta-Lactams– Penicillin
– Cephalosporins
– Piperacillin-Tazobactam
– Carbapenems
• Meropenem
• Ertapenem
![Page 10: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/10.jpg)
• Pharmacokinetics versus pharmacodynamics
•Pharmacokinetics mathematically describe the relationship of antibiotic concentration to time.
• Aabsorption, distribution, metabolism, elimination, half-life, volume of distribution, and area under the concentration-time curve (AUC).
![Page 11: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/11.jpg)
•Pharmacodynamics
•Describe the relationship of antibiotic concentration to pharmacologic effect or microorganism death.
• The three main pharmacodynamic parameters that are used are the
• peak to minimal inhibitory concentration ratio (peak/MIC), the AUC to MIC ratio (AUC/MIC)
![Page 12: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/12.jpg)
•Pharmacodynamics
• The time the drug concentration remains above the MIC (T>MIC).
• Concentration independent antimicrobials include: beta-lactams, vancomycin, macrolides, aztreonam, carbapenems, clindamycin, tetracyclines, quinupristin/dalfopristin, flucytosine, and azole antifungals.
![Page 13: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/13.jpg)
Pharmacodynamics
Concentration Dependent Killing
• Fluoroquinolones– Levofloxacin
– Ciprofloxacin
– Moxifloxacin
• Aminoglycosides– Amikacin
– Tobramycin
– Gentamicin
![Page 14: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/14.jpg)
Pharmacodynamics
AUC/MIC Dependent Killing
• Vancomycin
• Linezolid
• Clindamycin
• Macrolides– Azithromycin
– Clarithromycin
– Erythromycin
![Page 15: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/15.jpg)
Keys to Success
• Antibiotic covers potential infection/bacteria
• Dose of antibiotic is appropriate for treatment of infection and adjusted for renal/hepatic
impairment
• Antibiotic penetrates site of infection
• Antibiotic is being absorbed
• Adequate treatment duration
![Page 16: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/16.jpg)
Risk Factors for Resistance
• Antimicrobial therapy in the preceding 90 days
• Current hospitalization of 5 days or more
• High resistance rates in the unit
• Residence in a nursing home or extended care facility
• Immunocompromised
• Home wound care
• Chronic dialysis
![Page 17: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/17.jpg)
Gram Positive Agents
Vancomycin
Linezolid
Daptomycin
![Page 18: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/18.jpg)
Gram Positive Bacteria
• Cocci– Staphylococcus
• S. aureus• S. epidermidis
– Streptococcus• S. pyogenes (Group A)• S. viridians• S. pneumoniae
– Enterococcus• E. faecalis• E. Faecium
• Bacilli– Listeria monocytogenes– Bacillus anthracis– Corynebacterium species– Proprionibacterium acnes
![Page 19: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/19.jpg)
Vancomycin
• Spectrum of activity– Staph (MRSA, MSSA), strep, enterococcus, c. difficile colitis (oral)
• Mechanism of action– Inhibits synthesis of peptidoglycan/bacterial cell wall formation
• Dosing– Actual body weight– Loading dose = 25-30 mg/kg– Maintenance dose = 15-20 mg/kg– Usual Frequency = every 8-24h– Adjust dose for renal impairment
![Page 20: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/20.jpg)
Vancomycin
• Adverse effects– Redman syndrome
– Thrombocytopenia
– Possible nephrotoxicity ??
– Ototoxicity (rare) Ototoxicity is not associated with trough concentrations.
• Monitoring– Goal Trough = 15-20 mcg/mL
– Bacteremia, endocarditis, osteomyelitis, meningitis, pneumonia
– Initial: trough before 4th or 5th dose
– Maintenance: trough once weekly
![Page 21: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/21.jpg)
Vancomycin with Dialysis
• Continuous renal replacement therapy (CRRT)– 15mg/kg q24h– Hold dose if CRRT stopped > 8h– Trough before 4th or 5th dose
• Intermittent hemodialysis (iHD)– Pulse dosing with iHD– iHD removes ~25% of vancomycin– Goal Pre-iHD level < 24 mcg/mL– Initial dose = 15mg/kg x1 dose– Maintenance dose based on pre-iHD levels
![Page 22: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/22.jpg)
Linezolid
• Spectrum of activity
– Staph (MSSA, MRSA), strep, VRE
• Mechanism of action
– Binds to bacterial ribosomes to inhibit protein synthesis
• Bacteristatic against staph, vre but cidalagainst strep pneumon
• Time dependent killing
![Page 23: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/23.jpg)
Linezolid
• Adverse Effects– Myelosupression (pancytopenia, thrombocytopenia)
– GI upset
– Serotonin syndrome
• Drug interactions– Monoamine oxidase inhibitors (MAOI’s)
– Selective serotonin reuptake inhibitors (SSRI’s)
• Dosing– 600mg IV/PO q12h
![Page 24: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/24.jpg)
Linezolid
• Clinical Pearls
– May be used for vancomycin failure or intolerance
– Oral & IV formulations
– Bacteriostatic
– No renal adjustment
– May have prescribing restrictions
– Expensive
![Page 25: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/25.jpg)
Daptomycin• Spectrum of activity
– Staph (MSSA, MRSA), strep, enterococcus (VRE)
• Mechanism of action– Causes bacterial membranes to depolarize leading to inhibition of
protein, DNA, and RNA synthesis
• Typical Dosing– Adjust with renal impairment
– 4-6 mg/kg (actual weight) q24-48h
• Adverse Effects– Arthralgia
– Myalgia
– CPK elevations
![Page 26: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/26.jpg)
Daptomycin• Clinical Pearls
– Not for treatment of pneumonia
– Can use doses of 8-10 mg/kg for severe infections
– Monitor CPK at baseline and weekly
– Can falsely elevate INR
– May have prescribing restrictions
– Takes 30-60 minutes to reconstitute
– Expensive
![Page 27: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/27.jpg)
Gram Negative Agents
Aminoglycosides
Aztreonam
![Page 28: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/28.jpg)
Gram Negative Bacteria
Cocci
• Neisseria gonorrhoeae
• Neisseria meningitidis
• Moraxella catarrhalis
Bacilli
• Pseudomonas aeruginosa
• Acinetobacter species
• Citrobacter species
• Enterobacter species
• Klebsiella pneumoniae
• E. Coli
• H. influenzae
• Proteus mirabilis
• S. maltophilia
![Page 29: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/29.jpg)
https://www.facebook.com/groups/1451610115129555/#!/groups/1451610115129555/
Wellcome in our new group ..... Dr.SAMIR EL ANSARY
![Page 30: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/30.jpg)
Aminoglycosides
• Spectrum of activity
– Only gram negative, gram positive synergy
• Mechanism of action
– Bind bacterial ribosome and inhibit protein synthesis
• Adverse effects
– Nephrotoxicity
– Ototoxicity
– Prolonged neuromuscular blockade
Medications
Gentamicin Tobramycin Amkicacin
![Page 31: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/31.jpg)
• Aminoglycoside antibiotics possess nondepolarizing neuromuscular blocking
activity, which is additive or synergistic with the effects of the nondepolarizing
neuromuscular blocking agents used in anesthesia .
• Aminoglycosides cause presynaptic inhibition of acetylcholine release and postsynaptic
reduction in sensitivity
![Page 32: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/32.jpg)
Aminoglycosides
• Clinical Pearls– Used for
• Nosocomial infections• Double gram negative coverage • Endocarditis (synergy)
– Two dosing schemes• Traditional dosing• Extended interval dosing/once daily dosing
– Levels must be monitored• Traditional = peak & trough around 3rd dose• Extended interval = trough before 2nd dose
– Monitor Scr daily
![Page 33: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/33.jpg)
Aztreonam• Class
– Monobactam
• Spectrum of activity‒ Gram positive: none‒ Gram negative: most, except S. maltophilia
• Mechanism of action– Inhibit cell wall synthesis
• Dosing– Usual: 1-2g IV Q8h– Meningitis: 2g IV Q6-8h
• Adverse effects (rare)– Transient eosinophilia– LFT elevations– Thrombocytopenia
**Can be used with
penicillin allergy**
![Page 34: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/34.jpg)
Mixed Spectrum Agents
Cephalosporins
Piperacillin-Tazobactam
Carbapenems
![Page 35: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/35.jpg)
Spectrum of Activity Primary Use
First GenerationCefazolin (Ancef) (IV)
Cephalexin (Keflex) (PO)
• Simple Gram (+) , simple gram (-) , no
anaerobes. No ceph gets enterococci.• Simple SSTI, surgical prophylaxis
Second GenerationCefotetan (Cefotan) (IV)
Cefoxitin (Mefoxin) (IV)
Cefuroxime (Ceftin) (IV)
Cefaclor (Ceclor) (PO)
Cefprozil (Cefzil) (PO)
• Same spectrum as 1st Generation
• Cefotetan and Cefoxitin cover anaerobes
• Surgical prophylaxis if anaerobes,
URTI, UTI
Third GenerationCeftriaxone (Rocephin) (IV)
Cefotaxime (Claforan) (IV)
Ceftazadime (Fortaz) (IV)
Cefpodoxime (Vantan) (PO)
Cefdinir (Omnicef) (PO)
Cefixime (Suprax) (PO)
• Better gram (-)
• Ceftazadime-pseudomonas • PNA, meningitis
Fourth Generation
Cefepime (Maxipime) (IV)
• Good gram (+), nosocomial gram (-)
including pseudomonas
• No anaerobes
• Sepsis, HAP, neutropenic fever
Fifth GenerationCeftaroline (Teflaro)
• MRSA, MSSA, E. faecalis, s.pneumoniae,
• Some gram (-), NO pseudomonas• Pneumonia, SSTI
Cephalosporins
![Page 36: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/36.jpg)
• CABP pathogens, ceftaroline has activity against the Gram-positive organisms S.
pneumoniae, S. aureus and Streptococcus pyogenes, and Gram-negative species
(Haemophilus influenzae and CABP pathogens, ceftaroline has activity against the
Gram-positive organisms S. pneumoniae, S. aureus and Streptococcus pyogenes, and
Gram-negative species .
![Page 37: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/37.jpg)
Cephalosporins
• Clinical Pearls
– Do not cover enterococcus (except ceftaroline)– ↑ gram negative coverage with higher generations– Used for surgical prophylaxis– Anaerobic coverage
• Cefoxitin• Cefotetan
– Pseudomonas coverage• Ceftazidime• Cefepime
![Page 38: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/38.jpg)
Fluoroquinolines
Medications
Ciprofloxaci
nLevofloxacin Moxifloxacin
Gemifloxaci
n
Mechanism
of ActionInhibit DNA gyrase and topoisomerase IV inhibiting DNA synthesis
Spectrum of
Activity
• Gram Negative: Enterobacteriaceae, Haemophilus spp,
Neisseria spp and M. Catarrhalis
• Atypicals
PseudomonasPseudomonas
S. pneumoniae
Anaerobes
S. pneumoniae- - -
Clinical UseGram (-)
infections,
Bone/Joint
PNA, UTIPNA
NOT: UTIPNA
![Page 39: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/39.jpg)
Piperacillin-Tazobactam
• Spectrum of activity– Gram negative: P. aeruginosa, Enterbacteriaceae
– Gram positive: MSSA, Enterococci, Strep
– Anaerobes
• Mechanism of action– Inhibit cell wall synthesis
• Adverse effects– Gastrointestinal intolerance
– C. difficle colitis
– Interstitial nephritis
![Page 40: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/40.jpg)
• Mechanism of Action:
• Inhibit mucopeptide synthesis in the bacterial cell wall, thus results in formation of defective cell walls and osmotically unstable organisms susceptible to cell lysis
•Tazobactam acts as a beta-lactamase inhibitor and inactivates both plasmid and chromosome mediated beta-lactamases
![Page 41: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/41.jpg)
Carbapenems
Meropenem(Merem®)
Ertapenem (Invanz®)
Imipenem -Cilastatin
(Primaxin®)
Doripenem (Doribax®)
Mechanism of Action
Inhibit cell wall synthesis
Spectrum of Activity
Broad Spectrum: Gram (+), Gram (-), ESBL, Anaerobes NOT: MRSA
--NOT: Pseudomonas,
Enterococcus, Acinetobacter
-- --
Adverse Effects↓ PlateletsDrug Fever
Seizure↓ PlateletsDrug Fever
Common Use Meningitis Intra-abdominal Nocardia NOT: Pneumonia
![Page 42: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/42.jpg)
Carbapenems
• Clinical Pearls
– First line agent for extended spectrum beta-lactamase(ESBL) producing bacteria
– Extended infusion meropenem• ↑ time above MIC
– Reserved for severe infections
– May have prescribing restrictions
![Page 43: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/43.jpg)
Tigecycline
• Spectrum of activity– Enterococcus (including VRE), MSSA, MRSA, MRSE, anaerobes
– Not pseudomonas, proteus, providencia
• Mechanism of action– Binds to bacterial ribosomes to inhibit protein synthesis
• Dose– 100mg IV x 1 dose
– 50mg IV q12h
• Adverse effects– Nausea and vomiting
– Hyperbiliruminemia
![Page 44: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/44.jpg)
•Tigecycline has a spectrum of activity that includes anaerobes, many gram-
positive cocci and gram-negative bacilli w/ the exception of
Pseudomonas, Proteus, and Providencia.
•N/V may occur in up to 2/3rds of patients
![Page 45: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/45.jpg)
Tigecycline
• Clinical Pearls– No renal adjustment
– Hepatic dose adjustment (Child Pugh C)• 100mg IV x 1, then 25mg IV Q12h
– Used for resistant infections
– Do not use for • Ventilator associated pneumonia
• Bacteremia
– Can be used for • Intra-abdominal infections
• Skin & soft tissue infections
![Page 46: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/46.jpg)
•All-cause Mortality: •An increase in all-cause mortality has been observed
•The cause of this mortality risk difference has not been established.
•Tigecycline should be reserved for use in situations when alternative treatments are not suitable.•Death resulted from progression of infection•Especially in ventilator associated pneumonia•Reserve for use when other agents are not an
option
![Page 47: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/47.jpg)
Atypical Agents
Fluoroquinolones
Macrolides
Tetracyclines
![Page 48: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/48.jpg)
Atypical Bacteria
Agents• Fluoroquinolones
– Levofloxacin– Ciprofloxacin– Moxifloxacin– Gemifloxacin
• Macrolides– Azithromycin– Erythromycin– Clarithromycin
• Tetracyclines– Tetracycline– Doxycycline– Minocycline
Bacteria
• Mycoplasma
• Legionella pneumoniae
• Chlamydia pneumoniae
• Richettsia
• Actinomyces
![Page 49: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/49.jpg)
Commonly Encountered Infectious Disease Issues
![Page 50: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/50.jpg)
Clostridium Difficile
Antimicrobials per IDSA Guidelines
![Page 51: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/51.jpg)
Clostridium Difficile
• IDSA Recommendations
– No probiotics - ↑ Bloodstream infections
– Stop causative antimicrobials
– Repeat testing during the same episode is discouraged
– Vancomycin taper after second reoccurrence
– Dual antimicrobials
• Ileus = IV metronidazole + vancomycin enema
**PO vancomycin is only used to treat c. diff infection**
![Page 52: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/52.jpg)
• There is no evidence to support administration of combination therapy to patients with uncomplicated
CDI.
• Although hampered by its low statistical power, a recent trial did not show any trend toward better
results
when rifampin was added to a metronidazoleregimen.
• There is no evidence to support use of a combination of oral metronidazole and oral vancomycin.
![Page 53: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/53.jpg)
Allergic Reactions
• IgE reactions
– Anaphylaxis
– Bronchospasm
– Angioedema
– Pruritic rash
– Uticaria
– Hypotension
![Page 54: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/54.jpg)
Penicillin Allergy
Avoid UseIncidence of
ReactionMay Use
Cephalosporins
• 1st/2nd generation cephalosporin
2% • Aztreonam• 3rd/4th generation
cephalosporin
Carbapenems
• None? 0-11% • All carbapenems?• Aztreonam• Graded challenge or PCN
skin test
![Page 55: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/55.jpg)
•Penicillin-cephalosporin cross-reactivity studies that confirmed penicillin allergy by skin testing are superior
in design compared with those that diagnosed penicillin allergy by history alone.
•Another group of studies evaluated patients with positive penicillin skin tests (to penicilloyl polylysine
[PPL], penicillin G, and/or the minor determinant mixture [MDM]) who were challenged with
cephalosporins and found an overall reaction rate of 3.4 percent .
![Page 56: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/56.jpg)
• If this analysis is limited to studies published after 1980 (when cephalosporins were no longer
contaminated with penicillin), the reaction rate is reduced to 2 percent.
•Thus, approximately 2 percent of patients with skin-test proven sensitivity to penicillin can be expected to
react to cephalosporins.
•Range for cephalosporin reaction was 0-12% reported in the literature.
![Page 57: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/57.jpg)
Treatment Approach
![Page 58: Antibiotics 2015 in icu](https://reader033.vdocuments.net/reader033/viewer/2022042701/55a715f91a28ab1f358b486f/html5/thumbnails/58.jpg)
GOOD LUCK
SAMIR EL ANSARY
ICU PROFESSOR
AIN SHAMS
CAIRO
Global Critical Carehttps://www.facebook.com/groups/1451610115129555/#!/groups/145
1610115129555/ Wellcome in our new group ..... Dr.SAMIR EL ANSARY